For the past several years, the medical landscape regarding obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) has been dominated by a single, revolutionary class of drugs: GLP-1 receptor agonists. Marketed under blockbuster brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, these medications have provided unprecedented results in blood sugar control and significant weight loss for millions of patients. By mimicking hormones that signal satiety, these drugs have effectively "turned down" the biological urge to eat.
However, as these drugs have moved from niche treatments to household names, the medical community has begun to grapple with the limitations of the "appetite-suppression" model. Common gastrointestinal side effects, the risk of nutritional deficiencies, and—perhaps most concerning—the potential for muscle mass loss (sarcopenia) have spurred researchers to look for alternatives.
Now, a team of researchers at the University of California, Berkeley, has unveiled a fundamentally different approach. Instead of curbing the caloric intake that flows into the body, their latest study, published August 21 in Science Advances, proposes a way to ramp up the "outflow"—increasing the body’s metabolic rate to burn fat as fuel.
The Metabolic Seesaw: Taking In vs. Spending Out
To understand the novelty of the Berkeley team’s research, one must first look at the fundamental "levers" of body weight. According to Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and the study’s senior author, the body’s weight is a reflection of a simple equation: calories consumed versus energy expended.
"GLP-1s work almost entirely on the first lever," Näär explains. By inducing a sense of fullness, they reduce the total volume of fuel entering the system. While effective, this approach creates a caloric deficit that often forces the body to break down stored muscle tissue alongside fat, leading to the "frailty" risks often observed in patients on long-term weight-loss regimens.
The Berkeley team decided to pull the second lever: energy expenditure. Their focus is on a molecular compound known as 5-tetradecyloxy-2-furoic acid (TOFA). By activating the body’s internal "furnace," TOFA aims to encourage cells to oxidize fat at a higher rate, potentially allowing for weight loss that preserves lean muscle mass.
A Chronological Evolution: From 1970s Discovery to Modern Metabolic Biology
The history of TOFA is a classic example of "drug recycling"—taking a compound discovered decades ago and finding a new purpose through modern molecular insights.
The 1970s: The Discovery of ACC Inhibitors
TOFA was first identified in the 1970s as an inhibitor of acetyl-CoA carboxylase (ACC), an enzyme critical for the synthesis of fatty acids. In the decades that followed, several pharmaceutical companies attempted to utilize ACC inhibitors as a means of stopping the body from producing new lipids, hoping this would curb obesity.
The Stalled Progress
Despite early enthusiasm, the path for ACC inhibitors proved treacherous. Mid-stage clinical trials for various compounds in this class consistently ran into a significant safety barrier: they frequently triggered a spike in triglyceride levels. In the cardiovascular world, elevated triglycerides are a major red flag, often associated with an increased risk of heart disease. Consequently, none of these compounds achieved FDA approval for metabolic diseases.
The 2024 Breakthrough
The Berkeley team, led by Näär and first author Justin Y. Lee, a postdoctoral researcher at UCSF, revisited the compound with a fresh lens. Through their research, they discovered that TOFA does not simply act as a blunt-force ACC inhibitor. Instead, it engages a "coordinated metabolic response."
In their study, the team found that while TOFA does interfere with the production of lipids like cholesterol and triglycerides, it simultaneously activates PPARα and PPARδ—cellular receptors that essentially "switch on" the genes responsible for fat uptake and energy burning. This dual-action mechanism appears to be the "secret sauce" that allows TOFA to bypass the triglyceride-spiking side effects that doomed previous ACC inhibitors.
Supporting Data: The Evidence from the Lab
The efficacy of TOFA was rigorously tested in obese mice, with results that suggest a paradigm shift in how we might treat metabolic syndrome.
Metabolic Improvements
In experiments, mice treated with TOFA showed a remarkable improvement in insulin sensitivity and glucose control. Perhaps most impressively, the compound addressed signs of fatty liver disease, a condition that is notoriously difficult to treat with diet and exercise alone.
Preserving Muscle Mass
Unlike GLP-1 medications, which often result in a loss of both fat and muscle, the mice treated with TOFA lost fat while maintaining their lean muscle mass. This is a critical finding for long-term health; maintaining muscle mass is vital for metabolic health and physical function, particularly in aging populations.
Energy Expenditure
The researchers observed an increase in energy use by as much as 18% in the treated mice. Crucially, this did not happen because the mice were running around more or because their body temperatures were rising—common side effects of stimulants. Instead, the compound worked at the cellular level, forcing the mitochondria to "spend" more energy on metabolic processes.
Synergistic Potential
In one of the study’s most promising experiments, the team combined TOFA with existing GLP-1 medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). The results were additive, and in some cases, synergistic. The combination led to greater weight loss and better blood sugar regulation than either treatment could achieve alone. "We view it as complementary rather than a replacement," Näär noted.
Official Responses and Scientific Implications
The academic community has received the findings with cautious optimism. By demonstrating that one compound can outperform a two-drug approach—where researchers attempted to suppress lipid production and increase energy expenditure using two separate agents—the team provided strong evidence that the timing and location of these metabolic changes are crucial.
ReRx Therapeutics
Recognizing the commercial and therapeutic potential of their discovery, the researchers have moved beyond the laboratory. With the support of Berkeley’s robust entrepreneurship ecosystem—including the biotech incubator Nucleate and the Berkeley SkyDeck accelerator—the team has founded ReRx Therapeutics. This venture is tasked with the monumental challenge of translating these animal-model successes into human clinical trials.
The Road Ahead
Despite the enthusiasm, the researchers are careful to maintain a measured tone. "Human testing is still needed," the study authors emphasize. The physiological differences between murine models and human metabolism are significant, and the safety profile of TOFA in humans remains an open question. Potential side effects, the optimal dosage, and the long-term impact on systemic health will need to be scrutinized in Phase I and Phase II clinical trials.
The Broader Implications for Healthcare
If TOFA proves safe and effective in humans, the implications for the treatment of metabolic disease could be transformative.
- Reducing Sarcopenia: By providing a weight-loss tool that prioritizes fat metabolism over appetite suppression, clinicians might finally be able to decouple weight loss from muscle wasting.
- Combination Therapies: The future of metabolic medicine may not lie in a single "silver bullet" drug, but in "cocktails" that address the disease from multiple biological angles. A GLP-1 drug to manage appetite, paired with a metabolic activator like TOFA to burn off excess lipids, could provide a comprehensive solution for patients with severe metabolic syndrome.
- Broadening the Toolset: Many patients currently struggle with the side effects of GLP-1s, or find that their weight loss plateaus after the first year. Having a new class of medication that works on a different biological pathway offers a vital "second option" for those who do not respond well to current standards of care.
As the team at ReRx Therapeutics begins the arduous process of moving TOFA toward human trials, the medical community will be watching closely. While the "appetite-suppression era" has undoubtedly changed the lives of millions, the potential for a "metabolic-activation era" offers the next chapter in the fight against one of the world’s most pervasive health crises.
The research was supported by discretionary funds from UC Berkeley, with additional assistance from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. It represents a collaborative effort between departments of biology, medicine, and engineering, reflecting the interdisciplinary nature of modern pharmaceutical discovery.
